Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
about
Gemcitabine for platinum-resistant or recurrent ovarian cancerGemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategiesOutcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinomaPotent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine KinasePreclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancerHeavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancerRegional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancerChemotherapy for ovarian cancer: current concepts.Gemcitabine in the treatment of bladder cancer.Nucleoside analogues in the treatment of haematological malignancies.New developments in the treatment of ovarian cancer.Recent advances in the treatment of epithelial ovarian cancer.Clinical trials and progress with paclitaxel in ovarian cancerGemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.Phase II study of gemcitabine in patients with advanced pancreatic cancer.Role of chemotherapy in the management of ovarian cancer.Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Emerging role of pemetrexed in ovarian cancer.Second-line chemotherapy of epithelial ovarian cancer.Current therapies in ovarian cancer.Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy.How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations.Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.The role of gemcitabine in the treatment of other tumoursTreatment options in the management of ovarian cancer.Phase I study of gemcitabine using a once every 2 weeks schedule.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer.Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.Treatment of recurrent epithelial ovarian cancerWeekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
P2860
Q24241162-9F928EC9-FF7E-4399-8E07-B75EDFAFB4A0Q24645225-3B86DDB8-5EC4-4684-AB01-11633D771F42Q24791107-D3876EA3-9181-4BAA-BB83-8FE97329F14FQ28550404-1AA991D7-205D-49BF-8278-6B28922E0457Q31927266-C5A84E48-21B0-4F1E-8F43-DE57642CE8BFQ33337730-F4EE5E0D-D623-47C8-A2B9-C65C5A4C9B56Q33360212-F9039916-36E0-4C14-B369-9EE6BF470DAAQ33371474-05970E7F-EE22-4CD3-8793-019759F23A71Q33386456-3A26985A-DBD9-42BF-B879-DAC8F475E6DAQ33388219-89EE2AEE-D128-4690-923D-0D85CF407CA3Q33396261-184872B4-9C2F-433B-A211-DA3FC92FBDA2Q33597112-A45F1A6E-4153-4B2E-8947-44BC72603A9EQ33742794-5987C89E-A529-4A9D-810B-4C458F3CEA1AQ33938059-6BDDE182-D47B-4CCE-949F-5CEADB5E04F2Q34390281-0B97EA0B-913B-4941-8355-74800D11FB6CQ34481522-7CC4EE9B-BBE3-4929-9147-6272471D2328Q34481727-C1CAA348-AC78-49E7-AE9E-CFD12820F79BQ34510070-A83343A5-1A9C-4805-B8DD-0122CAA54FABQ34528724-7A1EC8F5-C45A-4F89-B15E-1A05E5D65E5DQ34732138-BB4018F8-B730-4049-A060-5911E69223C4Q34734126-C3E8108B-3146-4B9A-82CA-EA1F1AA48AF2Q34811103-32512393-166E-4E4A-997A-73C01C415812Q35015611-D383F2BB-343E-499F-B2F5-1DD384623AD5Q35070422-6C7DB27D-8D82-49A6-AF48-C50C46F74C16Q35087337-821BD371-1D17-403C-979C-ABB7FA5DA466Q35624530-2F9385C3-E1DB-47BA-9F3A-890A9C96DCBFQ35968737-5D40253C-4B92-4381-B80A-6390C77DFA7DQ35973865-B2483C57-7018-43E3-B549-26860D32045FQ35986419-C6CB5D51-AE62-4F3B-BEFC-2CA81F702DE7Q36114500-D6ECE1B0-56AD-465E-A381-D80307181A81Q36150781-B391C407-979D-4AAD-9CB5-7E965B6D32DDQ36431498-6D896FE0-E030-4CF9-992A-A71894149E75Q36488198-C9D2F7A7-D25B-4EB8-A759-EF38E47C066CQ36614893-A92C84E1-6657-4599-A23F-BB24CB426AA2Q36616830-FD5820D0-0460-46A0-B330-A14FF10A2D94Q36626071-D5A1BF99-5CF9-4F31-8C02-C38BD4BB8663Q37212223-AB292246-AA2D-40F4-A10B-DB583503EE9FQ37224624-84434B48-2B9B-4F1A-B5D4-85E6DE2FAC50Q37352629-9BA64418-2080-4D9E-96C0-42499ECE0DB2Q37634058-6E20ABC4-3487-4F8F-A56F-CB1F94C34A53
P2860
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
description
1994 nî lūn-bûn
@nan
1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@ast
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@en
type
label
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@ast
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@en
prefLabel
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@ast
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@en
P2093
P356
P1476
Phase II study of gemcitabine ...... eated ovarian cancer patients.
@en
P2093
P304
P356
10.1093/JNCI/86.20.1530
P407
P577
1994-10-01T00:00:00Z